Immunotherapy of Colorectal Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZOU Yifeng , WU Xiaojian , LAN Ping.

Department of Gastrointestinal and Pancreatic Surgery, The First Affiliated Hospital of Sun YatSen University, Guangzhou 510080, China;

Corresponding author：

Keywords：

Colorectal cancer Immunotherapy

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【Abstract】ObjectiveTo generally analyze the current situations and advancement of the study on immunotherapy for colorectal cancer.
MethodsThe pertinent published papers about the current situation and research advancement of the immunotherapy of colorectal cancer were retrospectively investigated. And also the immunogenicity and the varying principles of immunoresistance, the functional targets, the practicality, and some other characteristics of different immunotherapy for colorectal cancer were reviewed.
ResultsThe main treatments and the research focuses in the immunotherapy of colorectal cancer are initiative nonspecific immunotherapy, adoptive immunotherapy, monoclonal antibody immunotherapy, initiative specific immunotherapy, and targeted therapy. They work by fighting against the cancer itself, cutting off the tumor’s nutrition supply, activating the immune system specifically or breaking the immune tolerance and so on. Though there are still many problems unsolved, immunotherapy has a promising clinical prospect.
ConclusionAs a beneficial complement for surgery, chemotherapy and radiotherapy， immunotherapy plays an important auxiliary role in the combined therapy for colorectal cancer.

Citation： ZOU Yifeng,WU Xiaojian,LAN Ping.. Immunotherapy of Colorectal Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2006, 13(3): 358-361. doi: Copy

1.	[J]. Clin Cancer Res, 1999; 5(2)∶225.
2.	[J]. Cancer Treat Rev, 2000; 26(3)∶169.
3.	[J]. Gut, 1998; 43(4)∶445.
4.	[J]. Br J Cancer， 1999; 79(7-8)∶1262.
5.	[J]. Cancer Res, 2002; 62(18)∶5267.
6.	[J]. J Natl Cancer Inst, 2004; 96(15)∶1128.
7.	[J]. Oncology, 1996; 53(4)∶263.
8.	[J]. Ann Intern Med, 1995; 122(5)∶321.
9.	[J]. Ann Surg, 1989; 210(4)∶474.
10.	[J]. J Clin Invest, 2002; 110(2)∶185.
11.	[J]. Nat Biotechnol, 2002; 20(12)∶1221.
12.	[J]. Nature, 1993; 362(6423)∶841.
13.	[J]. Crit Rev Oncol Hematol， 1995; 19(3)∶183.
14.	[J]. Clin Cancer Res, 2001; 7(10)∶2958.
15.	[J]. World J Gastroenterol, 2003; 9(3)∶495.
16.	[J]. Cancer Immunol Immunother, 2002; 51(2)∶63.
17.	[J]. Crit Rev Oncol Hematol, 2001; 39(1-2)∶107.
18.
19.	[J]. Cancer Immunol Immunother, 2005; 26(1)∶1.
20.
21.	[J]. Cancer Res, 2004; 64(14)∶4995.
22.
23.	[J]. Exp Dermatol, 2001; 10(3)∶161.
24.	[J]. Clin Cancer Res, 2002; 8(9)∶2782.
25.	[J]. Clin Cancer Res, 2002; 8(7)∶2044.
26.
27.	[J]. Int J Cancer, 2004; 110(1)∶70.
28.
29.	[J]. Clin Cancer Res, 2003; 9(4)∶1347.
30.
31.	[J]. Cancer Res, 2003; 9(9)∶3235.
32.	[J]. J Nucl Med, 1990; 31(6)∶1035.
33.
34.	[J]. Cancer Immunol Immunother, 2006; 55(1)∶47.
35.	Foon KA, Yannelli J, BhattacharyaChatterjee M. Colorectal cancer as a model for immunotherapy.
36.	Yip D, Strickland AH, Karapetis CS, et al. Immunomodulation therapy in colorectal carcinoma.
37.	Todryk SM, Chong H, Vile RG, et al. Can immunotherapy by gene transfer tip the balance against colorectal cancer?.
38.	Mann B, Gratchev A, Bohm C, et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas.
39.	Somasundaram R, Jacob L, Swoboda R, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factorbeta.
40.	Smith RE, Colangelo L, Wieand HS, et al. Randomized trial of adjuvant therapy in colon carcinoma: 10year results of NSABP protocol C01.
41.	Brivio F, Lissoni P, Alderi G, et al. Preoperative interleukin2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
42.	Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage Ⅲ colon carcinoma: a final report.
43.	Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of highdose interleukin2 in the treatment of 652 cancer patients.
44.	Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity.
45.	Kershaw MH, Westwood JA, Hwu P. Dualspecific T cells combine proliferation and antitumor activity.
46.	Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo.
47.	Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factorrelated peptides and their receptors in human malignancies.
48.	Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
49.	Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.
50.	Sivanandham M, Stavropoulos CI, Kim EM, et al. Therapeutic effect of colon tumor cells expressing FLT3 ligand plus systemic IL2 in mice with syngeneic colon cancer.
51.	Birebent B, Somasundaram R, Purev E, et al. Antiidiotypic antibody and recombinant antigen vaccines in colorectal cancer patients.
52.	Saha A, Baral RN, Chatterjee SK, et al. CpG oligonucleotides enhance the tumor antigenspecific immune response of an antiidiotype antibodybased vaccine strategy in CEA transgenic mice.
53.	Saha A, Chatterjee SK, Foon KA, et al. Dendritic cells pulsed with an antiidiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
54.	Hunger RE, Brand CU, Streit M, et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GMCSF as adjuvant.
55.	Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
56.	Moulton HM, Yoshihara PH, Mason DH, et al. Active specific immunotherapy with a betahuman chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
57.	Sinibaldi Vallebona P, Rasi G, Pierimarchi P， et al. Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats.
58.	Welt S, Ritter G, Williams C Jr, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
59.	Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumorderived heatshock protein gp96 after liver resection for metastatic colorectal cancer.
60.	Buchegger F, Pelegrin A, Delaloye B, et al. Iodine131labeled MAb F(ab’)2 fragments are more efficient and less toxic than intact antiCEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.
61.	Koppe MJ, Oyen WJ, Bleichrodt RP, et al. Combination therapy using the cyclooxygenase2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.

1. [J]. Clin Cancer Res, 1999; 5(2)∶225.
2. [J]. Cancer Treat Rev, 2000; 26(3)∶169.
3. [J]. Gut, 1998; 43(4)∶445.
4. [J]. Br J Cancer， 1999; 79(7-8)∶1262.
5. [J]. Cancer Res, 2002; 62(18)∶5267.
6. [J]. J Natl Cancer Inst, 2004; 96(15)∶1128.
7. [J]. Oncology, 1996; 53(4)∶263.
8. [J]. Ann Intern Med, 1995; 122(5)∶321.
9. [J]. Ann Surg, 1989; 210(4)∶474.
10. [J]. J Clin Invest, 2002; 110(2)∶185.
11. [J]. Nat Biotechnol, 2002; 20(12)∶1221.
12. [J]. Nature, 1993; 362(6423)∶841.
13. [J]. Crit Rev Oncol Hematol， 1995; 19(3)∶183.
14. [J]. Clin Cancer Res, 2001; 7(10)∶2958.
15. [J]. World J Gastroenterol, 2003; 9(3)∶495.
16. [J]. Cancer Immunol Immunother, 2002; 51(2)∶63.
17. [J]. Crit Rev Oncol Hematol, 2001; 39(1-2)∶107.
18.
19. [J]. Cancer Immunol Immunother, 2005; 26(1)∶1.
20.
21. [J]. Cancer Res, 2004; 64(14)∶4995.
22.
23. [J]. Exp Dermatol, 2001; 10(3)∶161.
24. [J]. Clin Cancer Res, 2002; 8(9)∶2782.
25. [J]. Clin Cancer Res, 2002; 8(7)∶2044.
26.
27. [J]. Int J Cancer, 2004; 110(1)∶70.
28.
29. [J]. Clin Cancer Res, 2003; 9(4)∶1347.
30.
31. [J]. Cancer Res, 2003; 9(9)∶3235.
32. [J]. J Nucl Med, 1990; 31(6)∶1035.
33.
34. [J]. Cancer Immunol Immunother, 2006; 55(1)∶47.
35. Foon KA, Yannelli J, BhattacharyaChatterjee M. Colorectal cancer as a model for immunotherapy.
36. Yip D, Strickland AH, Karapetis CS, et al. Immunomodulation therapy in colorectal carcinoma.
37. Todryk SM, Chong H, Vile RG, et al. Can immunotherapy by gene transfer tip the balance against colorectal cancer?.
38. Mann B, Gratchev A, Bohm C, et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas.
39. Somasundaram R, Jacob L, Swoboda R, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factorbeta.
40. Smith RE, Colangelo L, Wieand HS, et al. Randomized trial of adjuvant therapy in colon carcinoma: 10year results of NSABP protocol C01.
41. Brivio F, Lissoni P, Alderi G, et al. Preoperative interleukin2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
42. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage Ⅲ colon carcinoma: a final report.
43. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of highdose interleukin2 in the treatment of 652 cancer patients.
44. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity.
45. Kershaw MH, Westwood JA, Hwu P. Dualspecific T cells combine proliferation and antitumor activity.
46. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo.
47. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factorrelated peptides and their receptors in human malignancies.
48. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
49. Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract.
50. Sivanandham M, Stavropoulos CI, Kim EM, et al. Therapeutic effect of colon tumor cells expressing FLT3 ligand plus systemic IL2 in mice with syngeneic colon cancer.
51. Birebent B, Somasundaram R, Purev E, et al. Antiidiotypic antibody and recombinant antigen vaccines in colorectal cancer patients.
52. Saha A, Baral RN, Chatterjee SK, et al. CpG oligonucleotides enhance the tumor antigenspecific immune response of an antiidiotype antibodybased vaccine strategy in CEA transgenic mice.
53. Saha A, Chatterjee SK, Foon KA, et al. Dendritic cells pulsed with an antiidiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
54. Hunger RE, Brand CU, Streit M, et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GMCSF as adjuvant.
55. Conry RM, Curiel DT, Strong TV, et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
56. Moulton HM, Yoshihara PH, Mason DH, et al. Active specific immunotherapy with a betahuman chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival.
57. Sinibaldi Vallebona P, Rasi G, Pierimarchi P， et al. Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats.
58. Welt S, Ritter G, Williams C Jr, et al. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer.
59. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumorderived heatshock protein gp96 after liver resection for metastatic colorectal cancer.
60. Buchegger F, Pelegrin A, Delaloye B, et al. Iodine131labeled MAb F(ab’)2 fragments are more efficient and less toxic than intact antiCEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.
61. Koppe MJ, Oyen WJ, Bleichrodt RP, et al. Combination therapy using the cyclooxygenase2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Immunotherapy of Colorectal Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content